Halozyme Therapeutics (HALO) stock price, revenue, and financials

Halozyme Therapeutics market cap is $5.9 b, and annual revenue was $267.59 m in FY 2020

$5.9 B

HALO Mkt cap, 14-Sept-2021

$89 M

Halozyme Therapeutics Revenue Q1, 2021
Halozyme Therapeutics Gross profit (Q1, 2021)70.8 M
Halozyme Therapeutics Gross profit margin (Q1, 2021), %79.5%
Halozyme Therapeutics Net income (Q1, 2021)27.9 M
Halozyme Therapeutics EBIT (Q1, 2021)50.7 M
Halozyme Therapeutics Cash, 31-Mar-2021499.5 M
Halozyme Therapeutics EV6.3 B
Get notified regarding key financial metrics and revenue changes at Halozyme TherapeuticsLearn more
Banner background

Halozyme Therapeutics Revenue

Halozyme Therapeutics revenue was $267.59 m in FY, 2020 which is a 36.5% year over year increase from the previous period.

Embed Graph

Halozyme Therapeutics Revenue Breakdown

Embed Graph

Halozyme Therapeutics revenue breakdown by business segment: 10.5% from Product Sales, 16.6% from Royalties, 23.0% from Revenues under Collaborative Agreements, 10.5% from Product Sales, 16.6% from Royalties and 23.0% from Revenues under Collaborative Agreements

Halozyme Therapeutics revenue breakdown by geographic segment: 7.5% from Belgium, 35.9% from Switzerland, 40.0% from United States, 11.4% from Ireland and 5.3% from Other

Halozyme Therapeutics Income Statement

Annual

USDFY, 2018FY, 2019FY, 2020

Revenue

151.9m196.0m267.6m

Revenue growth, %

29%37%

Cost of goods sold

10.1m45.5m43.4m

Gross profit

141.7m150.4m224.2m

Gross profit Margin, %

93%77%84%

R&D expense

150.3m140.8m34.2m

General and administrative expense

60.8m77.3m45.7m

Operating expense total

211.1m218.1m80.0m

EBIT

(69.3m)(67.6m)144.3m

EBIT margin, %

(46%)(34%)54%

Interest expense

18.0m11.6m20.4m

Pre tax profit

(79.8m)(72.3m)129.3m

Income tax expense

537.0k(11.0k)217.0k

Net Income

(80.3m)(72.2m)129.1m

EPS

(0.6)(0.5)0.9

Halozyme Therapeutics Balance Sheet

Annual

USDFY, 2018FY, 2019FY, 2020

Cash

57.9m120.2m147.7m

Accounts Receivable

30.0m59.4m97.7m

Prepaid Expenses

20.7m33.4m28.3m

Inventories

22.6m29.4m60.7m

Current Assets

427.8m543.4m554.8m

PP&E

7.5m10.9m10.6m

Total Assets

440.2m565.9m579.9m

Accounts Payable

4.1m6.4m1.9m

Short-term debt

91.5m19.5m397.2m

Current Liabilities

149.4m85.6m421.4m

Long-term debt

34.9m383.0m

Total Debt

126.4m402.6m397.2m

Common Stock

145.0k137.0k135.0k

Additional Paid-in Capital

780.5m695.1m625.5m

Retained Earnings

(531.4m)(603.7m)(474.6m)

Total Equity

248.9m91.8m151.0m

Debt to Equity Ratio

0.5 x4.4 x2.6 x

Debt to Assets Ratio

0.3 x0.7 x0.7 x

Financial Leverage

1.8 x6.2 x3.8 x

Halozyme Therapeutics Cash Flow

Annual

USDFY, 2018FY, 2019FY, 2020

Net Income

(80.3m)(72.2m)129.1m

Depreciation and Amortization

2.4m4.1m3.3m

Accounts Receivable

11.6m(29.4m)(38.3m)

Inventories

(17.5m)(6.7m)(31.4m)

Accounts Payable

5.7m4.6m(41.2m)

Cash From Operating Activities

(49.5m)(85.4m)55.5m

Purchases of PP&E

(4.7m)(4.0m)(2.5m)

Cash From Investing Activities

2.5m(5.5m)78.4m

Long-term Borrowings

(77.5m)(108.1m)(19.6m)

Cash From Financing Activities

(63.8m)153.2m(106.3m)

Net Change in Cash

(110.8m)62.2m27.5m

Interest Paid

16.9m9.0m6.5m

Income Taxes Paid

220.0k188.0k180.0k

Halozyme Therapeutics Ratios

USDFY, 2018

EV/EBIT

-31.5 x

EV/CFO

-44.1 x

Revenue/Employee

595.5k

Debt/Equity

0.5 x

Debt/Assets

0.3 x

Financial Leverage

1.8 x

P/E Ratio

(26.1)

Halozyme Therapeutics Operating Metrics

FY, 2018FY, 2019FY, 2020

Products

111

Partnered Products

335

Filed Trials Products

2

Phase III Trials Products

538

Phase II Trials Products

111

Phase I Trials Products

10910

Preclinical Phase Products

2

Patents (US)

394343

Patents (Europe)

390520460

Patent Applications

1007050

Halozyme Therapeutics Human Capital

Halozyme Therapeutics's employees are reported to be approximately 52% female and 48% male.

Gender

Y, 2020
Male (Senior Management)9.2%
Female (Senior Management)7.7%
Male31.8%
Female34.4%

Ethnicity

Y, 2020
Hispanic / Latino, percent6.9%
Asian, percent20.8%
White, percent59.4%
Other12.9%

Halozyme Therapeutics Employee Rating

3.432 votes
Culture & Values
3.5
Work/Life Balance
3.2
Senior Management
2.9
Salary & Benefits
3.5
Career Opportunities
2.9
Source